Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study
Journal of Gastroenterology and Hepatology · 2024
DOI: 10.1111/jgh.16537 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Tyng-Yuan Jang und 42 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatobiliary, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Tenofovir, Guanine, Antiviral Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Kaohsiung Medical University, Kaohsiung Medical University Hospital, Center For Intelligent Drug Systems and Smart Bio-devices (IDS2B).
Abstract (Originalsprache)
Background and Aim The benefits of entecavir (ETV) versus tenofovir disoproxil fumarate (TDF) in reducing the development of chronic hepatitis B (CHB)‐related hepatocellular carcinoma remain controversial. Whether mortality rates differ between patients with CHB treated with ETV and those treated with TDF is unclear.
Methods
A total of 2542 patients with CHB treated with either ETV or TDF were recruited from a multinational cohort. A 1:1 propensity score matching was performed to balance the differences in baseline characteristics between the two patient groups. We aimed to compare the all‐cause, liver‐related, and non‐liver‐related mortality between patients receiving ETV and those receiving TDF.
Results
The annual incidence of all‐cause mortality in the entire cohort was 1.0/100 person‐years (follow‐up, 15 757.5 person‐years). Patients who received TDF were younger and had a higher body mass index, platelet count, hepatitis B virus deoxyribonucleic acid levels, and proportion of hepatitis B e‐antigen seropositivity than those who received ETV. The factors associated with all‐cause mortality were fibrosis‐4 index > 6.5 (hazard ratio [HR]/confidence interval [CI]: 3.13/2.15–4.54, P < 0.001), age per year increase (HR/CI: 1.05/1.04–1.07, P < 0.001), alanine aminotransferase level per U/L increase (HR/CI: 0.997/0.996–0.999, P = 0.003), and γ‐glutamyl transferase level per U/L increase (HR/CI: 1.002/1.001–1.003, P < 0.001). No significant difference in all‐cause mortality was observed between the ETV and TDF groups (log–rank test, P = 0.69). After propensity score matching, no significant differences in all‐cause, liver‐related, or non‐liver‐related mortality were observed between the two groups.
Conclusions
Long‐term outcomes of all‐cause mortality and liver‐related and non‐liver‐related mortality did not differ between patients treated with ETV and those receiving TDF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hepatobiliary, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Center of Hepatitis Research, College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Program of Environmental and Occupational Medicine and Graduate Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, South Korea.
- Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
- Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan.
ORCID-Profile: Tyng-Yuan Jang, Dae Won Jun, Hidenori Toyoda, Chih-Wen Wang, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Masanori Atsukawa, Haruki Uojima, Hirokazu Takahashi, Ming-Lun Yeh, Chia-Yen Dai, Jee-Fu Huang, Chung-Feng Huang, Ming-Lung Yu
Förderung
- Kaohsiung Medical University
- Kaohsiung Medical University Hospital
- Center For Intelligent Drug Systems and Smart Bio-devices (IDS2B)
- Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Zitieren
APA
Jang, T. Y., Liang, P. C., Jun, D. W., Jung, J. H., Toyoda, H., Wang, C. W., Yuen, M. F., Cheung, K. S., Yasuda, S., Kim, S. E., Yoon, E. L., An, J., Enomoto, M., Kozuka, R., Chuma, M., Nozaki, A., Ishikawa, T., Watanabe, T., Atsukawa, M., …, & Yu, M. L. (2024). Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16537
Vancouver
Jang TY, Liang PC, Jun DW, Jung JH, Toyoda H, Wang CW, et al. Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16537
BibTeX
@article{Jang2024,
author = {Jang, Tyng-Yuan and Liang, Po-Cheng and Jun, Dae Won and Jung, Jang Han and Toyoda, Hidenori and Wang, Chih-Wen and Yuen, Man-Fung and Cheung, Ka Shing and Yasuda, Satoshi and Kim, Sung Eun and Yoon, Eileen L and An, Jihyun and Enomoto, Masaru and Kozuka, Ritsuzo and Chuma, Makoto and Nozaki, Akito and Ishikawa, Toru and Watanabe, Tsunamasa and Atsukawa, Masanori and Arai, Taeang and Hayama, Korenobu and Ishigami, Masatoshi and Cho, Yong Kyun and Ogawa, Eiichi and Kim, Hyoung Su and Shim, Jae-Jun and Uojima, Haruki and Jeong, Soung Won and Ahn, Sang Bong and Takaguchi, Koichi and Senoh, Tomonori and Buti, Maria and Vargas-Accarino I, Elena and Abe, Hiroshi and Takahashi, Hirokazu and Inoue, Kaori and Yeh, Ming-Lun and Dai, Chia-Yen and Huang, Jee-Fu and Huang, Chung-Feng and Chuang, Wan-Long and Nguyen, Mindie H and Yu, Ming-Lung},
title = {Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study},
journal = {Journal of Gastroenterology and Hepatology},
year = {2024},
doi = {10.1111/jgh.16537}
}
EUVIMED